News
13d
Enrolment in third phase clinical trials for India’s first dengue vaccine nearly complete, says ICMR
ICMR and Panacea Biotec conduct third phase trials for indigenous dengue vaccine in India with promising results.
The new vaccine aims to provide protection against all four dengue serotypes. Read more at straitstimes.com. Read more at ...
12d
India’s first dengue vaccine: ICMR says phase-3 clinical trial enrolment to be completed by October
Phase-III trial of indigenous one-shot dengue vaccine by Panacea Biotec shows promising results in India, aiming for ...
Enrolment of about 10,500 participants in the phase III clinical trial of the indigenous one-shot Panacea Biotec developed ...
The vaccine strain (TV003/TV005), originally developed by the US National Institutes of Health (NIH), has shown promising ...
WHO’s new global guidance helps clinicians manage dengue, Zika, chikungunya, and yellow fever with protocols for fluids, ...
For years now, scientists have tried to develop a safe and effective dengue vaccine. The challenge however, is that there are four different types of dengue viruses, and a common vaccine must protect ...
TheHealthSite on MSN12d
WHO Issues First-Ever Clinical Guidelines For Dengue, Zika, Chikungunya, And Yellow Fever Amid Sudden Spike In Cases
WHO has issued guidelines to tackle the arbovirus diseases, which continue to be a major threat to life. Read on to know it ...
An ongoing Phase III clinical trial of DengiAll, a one-shot dengue vaccine developed by Panacea Biotec, is progressing in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback